Article
Assessment of genotoxicity associated with hydroxyurea therapy in children with sickle cell anemia.
Mutation research - 30 Apr 2010
Flanagan Jonathan M, Howard Thad A, Mortier Nicole, Avlasevich Svetlana L, Smeltzer Matthew P, Wu Song, Dertinger Stephen D, Ware Russell E
Abstract excerpt
Hydroxyurea induces fetal hemoglobin, improves laboratory parameters, and ameliorates clinical complications of sickle cell anemia (SCA), but its long-term efficacy and safety in this patient population remain incompletely defined. Although generally considered non-DNA reactive, an important safety concern is that hydroxyurea may indirectly cause genotoxic damage. To better address this safety issue of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.